Turn Therapeutics (NASDAQ:TTRX – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, FiscalAI reports.
Turn Therapeutics Stock Up 3.3%
Shares of Turn Therapeutics stock opened at $9.79 on Tuesday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 8.83. The company’s fifty day simple moving average is $11.70 and its two-hundred day simple moving average is $7.16. The company has a market cap of $298.92 million and a P/E ratio of -33.76. Turn Therapeutics has a 12-month low of $2.57 and a 12-month high of $16.45.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on TTRX. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Weiss Ratings downgraded Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Zacks Research raised Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Lucid Cap Mkts raised Turn Therapeutics to a “strong-buy” rating in a research report on Thursday, September 24th. Finally, Wall Street Zen cut Turn Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.00.
Read Our Latest Analysis on Turn Therapeutics
Institutional Investors Weigh In On Turn Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. TD Waterhouse Canada Inc. bought a new stake in shares of Turn Therapeutics during the 3rd quarter valued at about $40,000. Bank of America Corp DE bought a new position in Turn Therapeutics in the second quarter worth about $103,000. Jefferies Financial Group Inc. purchased a new stake in Turn Therapeutics in the second quarter worth about $119,000. HighTower Advisors LLC lifted its holdings in Turn Therapeutics by 23.3% in the third quarter. HighTower Advisors LLC now owns 24,279 shares of the company’s stock worth $349,000 after buying an additional 4,595 shares during the period. Finally, Bridgewater Advisors Inc. bought a new stake in Turn Therapeutics during the 2nd quarter valued at approximately $242,000.
About Turn Therapeutics
Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.
Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.
Read More
- Five stocks we like better than Turn Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Turn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
